M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 551.6 INR -0.28% Market Closed
Market Cap: 1T INR
Have any thoughts about
Mankind Pharma Ltd?
Write Note

Mankind Pharma Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mankind Pharma Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
M
Mankind Pharma Ltd
NSE:MANKIND
Depreciation & Amortization
â‚ą4B
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Depreciation & Amortization
â‚ą14.7B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Depreciation & Amortization
â‚ą10.4B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Depreciation & Amortization
â‚ą25.5B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Depreciation & Amortization
â‚ą7.6B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Depreciation & Amortization
â‚ą8.1B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mankind Pharma Ltd
Glance View

Market Cap
1T INR
Industry
Pharmaceuticals

Mankind Pharma Ltd. stands out as one of India's leading pharmaceutical companies, renowned for its commitment to developing and delivering affordable healthcare solutions. Founded in 1991, Mankind has carved a niche in the industry by focusing on high-quality generic medicines, over-the-counter (OTC) products, and niche therapeutics. With an impressive portfolio of over 800 products spanning various therapeutic segments, including cardiology, gynecology, dermatology, and antibiotics, the company has been instrumental in improving access to medications across the country. Mankind's innovative approach to drug development and its robust research and development capabilities support its strategy of launching products that fill critical gaps in the market. As an investor, Mankind Pharma presents a compelling opportunity due to its impressive growth trajectory and strategic expansion plans. The company has embraced a strong distribution network that not only reaches urban centers but also penetrates rural markets, enhancing its sales potential. Recently, Mankind has been making waves with its ambitious plans for international expansion, eyeing markets in Asia and Africa to leverage its production capabilities and widen its global footprint. With strong financial performance demonstrated through consistent revenue growth, coupled with a commitment to corporate governance and sustainable practices, Mankind Pharma is poised for long-term success, making it an enticing prospect for those looking to invest in the burgeoning pharmaceutical sector.

MANKIND Intrinsic Value
1 183 INR
Overvaluation 54%
Intrinsic Value
Price
M

See Also

What is Mankind Pharma Ltd's Depreciation & Amortization?
Depreciation & Amortization
4B INR

Based on the financial report for Mar 31, 2024, Mankind Pharma Ltd's Depreciation & Amortization amounts to 4B INR.

What is Mankind Pharma Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
50%

Over the last year, the Depreciation & Amortization growth was 22%. The average annual Depreciation & Amortization growth rates for Mankind Pharma Ltd have been 50% over the past three years .

Back to Top